PATENT CLAIM ANALYSIS

Application Number: 16040012
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "294000"]

Abstract:
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.

Claim (Index 1):
A method of transitioning a subject having a movement disorder from tetrabenazine to deutetrabenazine for the treatment of abnormal involuntary movement, comprising:\n a) discontinuing a daily amount of tetrabenazine; and b) administering an initial daily amount of deutetrabenazine the next day to the subject, wherein said initial daily amount is about 30% to about 70% of the daily amount of the tetrabenazine and is about 6 mg/day to about 48 mg/day, administered in one or two doses;\n wherein the daily amount of tetrabenazine was administered to the subject for the treatment of the abnormal involuntary movement; and \n wherein the transitioning results in at least a maintenance of abnormal involuntary movement control in the subject.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 95.0
- Lexical Diversity: 1.16667
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14900028', '11355339', '12638227', '14307195', '11340802']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6999558196524178
- 35 USC 102 Novelty (BERT): 0.5270977015551095
- Combined Prediction Score: 0.6826700078426869
- Mean Citation Score: 254.932838
- Max Citation Score: 300.44366
- Similarity Product: 182.7662805588889

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test